two-year follow-up results from keynote-045 study in urothelial carcinoma
Published 6 years ago • 75 plays • Length 1:54Download video MP4
Download video MP3
Similar videos
-
1:48
what does the 2-year follow-up tell us about the use of pembrolizumab for advanced bladder cancer?
-
1:09
keynote-045 – pembrolizumab as second-line treatment in urothelial carcinoma
-
0:51
impact of the keynote-045 study comparing pembrolizumab and chemotherapy in bladder cancer
-
1:18
dr. plimack on keynote-045 trial for pembrolizumab in urothelial carcinoma
-
0:58
significance of keynote-045 trial of pembrolizumab vs chemotherapy in urothelial carcinoma
-
1:58
results for first-line pembrolizumab in advanced urothelial carcinoma
-
1:23
how effective is pembrolizumab in cisplatin-ineligible bladder cancer? results from keynote-052
-
8:55
andrea necchi, esmo 2019 - keynote-045 trial in advanced urothelial cancer
-
2:22
keynote-057: extended follow-up of pembrolizumab in bladder cancer
-
6:35
immunotherapy in second-line advanced bladder cancer
-
2:15
results of a first-line study of pembrolizumab in advanced urothelial cancer
-
1:53
discussing recent advances and clinical trials in bladder cancer
-
0:54
dr. balar on results of keynote-052 in urothelial cancer
-
10:05
pout: extended follow-up results
-
1:29:54
examining the state of the science on new therapies in bladder cancer
-
1:09:47
evidence and insights on innovative treatment for bladder cancer
-
43:17
case-based panel discussion: muscle-invasive bladder cancer
-
1:47
current and upcoming clinical trials in bladder cancer